Therapeutic uses of curcumin analogs for treatment of prostate cancer
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Nov 22, 2016
Grant Date -
Jan 15, 2015
app pub date -
Jun 27, 2014
filing date -
Jul 2, 2013
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
This invention relates generally to methods of treating aggressive cancers, such as hormone-refractory metastatic prostate cancer, by exposing the aggressive cancer cells to curcumin analogs having the claimed structural scaffolds and side groups. The anticancer effects of curcumin are associated with its influence on numerous growth factors within the cells. However, its clinical development has been limited by its suboptimal pharmacokinetics and poor bioavailability caused by poor solubility in water and rapid in vivo metabolism. There is the need to develop new and improved curcumin analogs with better potency, water solubility, and in vivo metabolic stability, as well as retained safety profiles. Curcumin analogs having one of the claimed four novel scaffolds with basic heteroaromatic side groups show the ability to decrease aggressive cancer cell viability and to inhibit aggressive cancer cell growth.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully